We’re thrilled to announce that our portfolio company Tubulis has received FDA Fast Track designation for TUB-040, their lead antibody-drug conjugate (ADC) candidate for platinum-resistant ovarian cancer.
This next-generation ADC, based on Tubulis’ proprietary P5 technology, has demonstrated superior biophysical properties and effective, durable responses in preclinical models.
TUB-040 is currently being evaluated in a multicenter Phase I/IIa study in patients with platinum-resistant high-grade ovarian cancer or relapsed/refractory adenocarcinoma non-small cell lung cancer. The Fast Track status will allow for increased interaction with the FDA, supporting expedited development and regulatory review.
This milestone underscores the potential of Tubulis’ innovative approach to address the unmet need in ovarian cancer treatment, particularly for patients who have developed resistance to platinum-based therapies. We’re proud to support Tubulis in their mission to transform the landscape of cancer therapeutics.
More information in the press release under the following link
More about Tubulis
